Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is the second most common leukemia in adults. Rapid evolution in the science and approval of drugs for AML presents a continuing challenge for clinicians, particularly given the number of changes in the past 2 years. Genetic studies and diagnostic testing recommendations have the potential to alter therapy and increase overall survival substantially. Identification of specific mutations and targeting therapy on an individualized basis is more possible than ever. These advances in diagnosis and management of AML provide an opportunity to improve patient outcomes.
This education will provide members of the multidisciplinary cancer care team with the latest information to improve their knowledge and confidence in the diagnosis and treatment of AML through interactive online activities.